2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
ASCO® 2024 Insights: "Multi-Center Phase II Trial Investigating Safety & Efficacy of Osimertinib + Consolidative SABR in Advanced EGFRm NSCLC"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Sawsan Rashdan
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Sawsan Rashdan
Login to view comments.
Click here to Login